EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Randomized dose-response trial of n–3 fatty acids in hormone receptor negative breast cancer survivors – impact on breast adipose oxylipin and DNA methylation patterns

David E Frankhouser, Todd DeWees, Isabel F Snodgrass, Rachel M Cole, Sarah Steck, Danielle Thomas, Chidimma Kalu, Martha A Belury, Steven K Clinton, John W Newman, Lisa D Yee

The American Journal of Clinical Nutrition · 2025

DOI: 10.1016/j.ajcnut.2025.04.021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The American Journal of Clinical Nutrition, 2025. Verfasst von David E Frankhouser und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational and Quantitative Medicine, City of Hope, Duarte, CA. Hauptthemen laut MEDLINE: Breast Neoplasms, Oxylipins, DNA Methylation, Adipose Tissue. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Increasing evidence suggests the unique susceptibility of estrogen receptor and progesterone receptor negative [ERPR(-)] breast cancer to dietary fat amount and type. Dietary n-3 (ω-3) polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may modulate breast adipose fatty acids and downstream metabolites to counteract procarcinogenic signaling in the mammary microenvironment. OBJECTIVES: We aimed to determine effects of ∼1 to 5 g/d EPA+DHA over 12 mo on breast adipose fatty acid and oxylipin profiles in survivors of ERPR(-) breast cancer, a high-risk molecular subtype. METHODS: We conducted a proof-of-concept 12-mo randomized double-blind trial comparing ∼5 g/d and ∼1 g/d EPA+DHA supplementation in females within 5 y of completing standard therapy for ERPR(-) breast cancer Stages 0 to III. Blood and breast adipose tissue specimens were collected every 3 mo for fatty acid, oxylipin, and DNA methylation (DNAm) analyses. RESULTS: A total of 51 participants completed the 12-mo intervention. Study treatments were generally well tolerated. Although both doses increased n-3 PUFAs from baseline in breast adipose, erythrocytes, and plasma, the 5 g/d supplement was more potent with differences (% total fatty acids) of 0.76 (95% confidence interval [CI]: 0.56, 0.96), 6.25 (95% CI: 5.02, 7.48), and 5.89 (95% CI: 4.53, 7.25), respectively. The 5 g/d dose also reduced plasma triglycerides from baseline, with changes (mg/dL) of 27.38 (95% CI: 10.99, 43.78) and 24.58 (95% CI: 9.05, 40.10) at 6 and 12 months, respectively. Breast adipose oxylipins showed dose-dependent increases in DHA and EPA metabolites. Distinct DNAm patterns in adipose tissue after 12 mo suggest potential downregulation of aberrant lipid metabolism pathways at the 5 g/d dose. CONCLUSIONS: Over 1 y, EPA+DHA dose-dependently increased breast adipose concentrations of these fatty acids and their derivative oxylipin metabolites and produced differential DNAm profiles involved in metabolism-related pathways critical to ERPR(-) breast cancer development. This distinct metabolic and epigenetic modulation of the breast microenvironment is achievable with high-dose n-3 PUFA supplementation. This trial was registered at clinicaltrials.gov as NCT02295059.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsOxylipinsDNA MethylationAdipose TissueFatty Acids, Omega-3BreastHumansFemaleMiddle AgedDouble-Blind MethodDietary SupplementsAdultReceptors, ProgesteroneDocosahexaenoic AcidsReceptors, EstrogenEicosapentaenoic AcidAgedCancer SurvivorsDose-Response Relationship, Drug

Stichwörter der Autor:innen

breast adipose DNA methylationbreast adipose oxylipinsbreast cancerdose-responsen–3 PUFAsrandomized clinical trial

Substanzen

OxylipinsFatty Acids, Omega-3Receptors, ProgesteroneDocosahexaenoic AcidsReceptors, EstrogenEicosapentaenoic Acid

Autor:innen und Institutionen

  • Department of Computational and Quantitative Medicine, City of Hope, Duarte, CA.
  • Department of Computational and Quantitative Medicine, City of Hope, Duarte, CA; Department of Surgery, City of Hope, Duarte, CA.
  • University of California Davis West Coast Metabolomics Center, Genome Center, University of California Davis, Davis, CA.
  • Department of Food Science and Technology, The Ohio State University, Columbus, OH.
  • The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Department of Surgery, City of Hope, Duarte, CA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Frankhouser, D. E., DeWees, T., Snodgrass, I. F., Cole, R. M., Steck, S., Thomas, D., Kalu, C., Belury, M. A., Clinton, S. K., Newman, J. W., & Yee, L. D. (2025). Randomized dose-response trial of n–3 fatty acids in hormone receptor negative breast cancer survivors – impact on breast adipose oxylipin and DNA methylation patterns. The American Journal of Clinical Nutrition. https://doi.org/10.1016/j.ajcnut.2025.04.021

Vancouver

Frankhouser DE, DeWees T, Snodgrass IF, Cole RM, Steck S, Thomas D, et al. Randomized dose-response trial of n–3 fatty acids in hormone receptor negative breast cancer survivors – impact on breast adipose oxylipin and DNA methylation patterns. The American Journal of Clinical Nutrition. 2025. doi:10.1016/j.ajcnut.2025.04.021

BibTeX
@article{Frankhouser2025,
  author = {Frankhouser, David E and DeWees, Todd and Snodgrass, Isabel F and Cole, Rachel M and Steck, Sarah and Thomas, Danielle and Kalu, Chidimma and Belury, Martha A and Clinton, Steven K and Newman, John W and Yee, Lisa D},
  title = {Randomized dose-response trial of n–3 fatty acids in hormone receptor negative breast cancer survivors – impact on breast adipose oxylipin and DNA methylation patterns},
  journal = {The American Journal of Clinical Nutrition},
  year = {2025},
  doi = {10.1016/j.ajcnut.2025.04.021}
}
Kostenlos starten →